A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Interim analysis

David G. Armstrong, Dennis P. Orgill, Robert Galiano, Paul M. Glat, Lawrence Didomenico, Alexander Reyzelman, Robert Snyder, William W. Li, Marissa Carter, Charles M. Zelen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We desired to carefully evaluate a novel autologous heterogeneous skin construct in a prospective randomised clinical trial comparing this to a standard-of-care treatment in diabetic foot ulcers (DFUs). This study reports the interim analysis after the first half of the subjects have been analysed. Fifty patients (25 per group) with Wagner 1 ulcers were enrolled at 13 wound centres in the United States. Twenty-three subjects underwent the autologous heterogeneous skin construct harvest and application procedure once; two subjects required two applications due to loss of the first application. The primary endpoint was the proportion of wounds closed at 12 weeks. There were significantly more wounds closed in the treatment group (18/25; 72%) vs controls (8/25; 32%) at 12 weeks. The treatment group achieved significantly greater percent area reduction compared to the control group at every prespecified timepoint of 4, 6, 8, and 12 weeks. Thirty-eight adverse events occurred in 11 subjects (44%) in the treatment group vs 48 in 14 controls (56%), 6 of which required study removal. In the treatment group, there were no serious adverse events related to the index ulcer. Two adverse events (index ulcer cellulitis and bleeding) were possibly related to the autologous heterogeneous skin construct. Data from this planned interim analysis support that application of autologous heterogeneous skin construct may be potentially effective therapy for DFUs and provide supportive data to complete the planned study.

Original languageEnglish (US)
Pages (from-to)64-75
Number of pages12
JournalInternational Wound Journal
Volume19
Issue number1
DOIs
StatePublished - Jan 2022

Keywords

  • biological products
  • diabetic foot
  • randomised controlled trial
  • ulcer
  • wound healing

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Fingerprint

Dive into the research topics of 'A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Interim analysis'. Together they form a unique fingerprint.

Cite this